Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells

AAPS Journal

Volumn 10, Issue 4, 2008, Pages 565-576

  Magadala, Padmaja ^a   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

EGFP N1 plasmid DNA; EGFR targeted delivery; Panc 1 human pancreatic adenocarcinoma cells; Transgene expression; Type B gelatin nanoparticles

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATIN; MACROGOL; NANOCARRIER; NANOPARTICLE; PEPTIDE; PLASMID DNA; DNA; DRUG CARRIER; GREEN FLUORESCENT PROTEIN; NANOCAPSULE;

ARTICLE; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONVIRAL GENE DELIVERY SYSTEM; PANCREAS CANCER; PROTEIN TARGETING; TRANSGENE; ADENOCARCINOMA; AGAR GEL ELECTROPHORESIS; CELL SURVIVAL; DRUG DELIVERY SYSTEM; GENE TRANSFER; GENETICS; METHODOLOGY; PANCREAS TUMOR; PLASMID; REPORTER GENE; SCANNING ELECTRON MICROSCOPY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; DNA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ELECTROPHORESIS, AGAR GEL; GELATIN; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; NANOCAPSULES; PANCREATIC NEOPLASMS; PLASMIDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION;

EID: 65549143860     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9065-0     Document Type: Article

References (37)

1. A. Jemal, R. C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E. J. Feuer, and M. J. Thun. Cancer statistics, 2004. CA Cancer J. Clin. 54:8-29 (2004).
2. B. E. Huber. Gene therapy strategies for treating neoplastic disease. Ann. N. Y. Acad. Sci. 716:6-11 (1994). discussion 20-12.
3. J. A. Roth. Adenovirus p53 gene therapy. Expert. Opin. Biol. Ther. 6:55-61 (2006).
4. J. A. Roth. Gene replacement strategies for lung cancer. Curr. Opin. Oncol. 10:127-132 (1998).
5. J. A. Roth. Gene replacement strategies for cancer. Isr. J. Med. Sci. 32:89-94 (1996).
6. J. A. Roth, and S. F. Grammer. Gene replacement therapy for non-small cell lung cancer: A review. Hematol. Oncol. Clin. North Am. 18:215-229 (2004).
7. J. A. Roth, and S. F. Grammer. Tumor suppressor gene therapy. Methods Mol. Biol. 223:577-598 (2003).
8. J. A. Roth, S. F. Grammer, S. G. Swisher, R. Komaki, J. Nemunaitis, J. Merritt, and R. E. Meyn. P53 gene replacement for cancer-interactions with DNA damaging agents. Acta. Oncol. 40: 739-744 (2001).
9. J. A. Roth, S. G. Swisher, and R. E. Meyn. p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park). 13:148-154 (1999).
10. P. D. Wadhwa, S. P. Zielske, J. C. Roth, C. B. Ballas, J. E. Bowman, and S. L. Gerson. Cancer gene therapy: Scientific basis. Annu. Rev. Med. 53:437-452 (2002).
11. D. Jacob, J. J. Davis, L. Zhang, H. Zhu, F. Teraishi, and B. Fang. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther. 12(2):109-115 (2005).
12. A. S. Pearson, M. Bouvet, D. B. Evans, and J. A. Roth. Gene therapy and pancreatic cancer. Front Biosci. 3:E230-237 (1998).
13. T. Blessing, J. S. Remy, and J. P. Behr. Monomolecular collapse of plasmid DNA into stable virus-like particles. Proc. Natl. Acad. Sci. U. S. A. 95(4):1427-1431 (1998).
14. E. Marshall. Gene therapy on trial. Science. 288:951-957 (2000).
15. E. Check. Gene therapy: Shining hopes dented - but not dashed. Nature. 420:735 (2002).
16. C. E. Thomas, A. Ehrhardt, and M. A. Kay. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5):346-358 (2003).
17. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release. 114(1):100-109 (2006).
18. J. Panyam, and V. Labhasetwar. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55:329-347 (2003).
19. M. Dellian, F. Yuan, V. S. Trubetskoy, V. P. Torchilin, and R. K. Jain. Vascular permeability in a human tumour xenograft: Molecular charge dependence. Br. J. Cancer. 82(9):1513-1518 (2000).
20. M. D. Bhavsar, and M. M. Amiji. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech. 9:288-294 (2008).
21. M. D. Bhavsar, and M. M. Amiji. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene. Ther. 15(17):1200-1209 (2008).
22. M. D. Bhavsar, and M. M. Amiji. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Release. 119:339-348 (2007).
23. M. D. Bhavsar, S. B. Tiwari, and M. M. Amiji. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J. Control. Release. 110:422-430 (2006).
24. G. Kaul, and M. Amiji. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J. Drug Target. 12:585-591 (2004).
25. G. Kaul, and M. Amiji. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: In vitro and in vivo studies. Pharm. Res. 22:951-961 (2005).
26. S. Kommareddy, and M. Amiji. Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine. 3: 32-42 (2007).
27. S. Kommareddy, and M. Amiji. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J. Pharm. Sci. 96:397-407 (2007).
28. S. Kommareddy, and M. Amiji. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug. Chem. 16:1423-1432 (2005).
29. S. Kommareddy, and M. Amiji. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther. 14: 488-498 (2007).
30. C. Neves, V. Escriou, G. Byk, D. Scherman, and P. Wils. Intracellular fate and nuclear targeting of plasmid DNA. Cell Boil. Toxicol. 15:193-202 (1999).
31. K. Tobita, H. Kijima, S. Dowaki, H. Kashiwagi, Y. Ohtani, Y. Oida, H. Yamazaki, M. Nakamura, Y. Ueyama, M. Tanaka, S. Inokuchi, and H. Makuuchi. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int. J. Mol. Med. 11:305-309 (2003).
32. Y. Yamanaka, H. Friess, M. S. Kobrin, M. Buchler, H. G. Beger, and M. Korc. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 13:565-569 (1993).
33. T. A. Jarvinen, and E. Ruoslahti. Molecular changes in the vasculature of injured tissues. Am. J. Pathol. 171:702-711 (2007).
34. Z. Li, R. Zhao, X. Wu, Y. Sun, M. Yao, J. Li, Y. Xu, and J. Gu. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19:1978-1985 (2005).
35. S. Zitzmann, V. Ehemann, and M. Schwab. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 62:5139-5143 (2002).
36. V. Guillemard, H. Nedev, A. Berezov, R. Murali, and H. U. Saragovi. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol. 24(6):351-358 (2005).
37. P. Chan, H. P. Nestler, and W. T. Miller. Investigating the substrate specificity of the HER2/Neu tyrosine kinase using peptide libraries. Cancer Lett. 160(2):159-169 (2000).